Highlighted research

ELISpot important in evaluating SARS-CoV-2 vaccine efficacy

Published: July 28, 2020

Updated: October 13, 2023

Two highly interesting and similar papers, from Oxford University and Wuhan University, were published on the same day (July 20, 2020) in The Lancet, showing promising results for SARS-CoV-2 vaccine candidates.

Both studies include a phase 2 clinical trial of two slightly different adenovirus-vectored vaccines. Both showed no adverse events but nice humoral and cellular responses at a dose of 5 x 10^10 viral particles. And, interestingly, both studies utilized our IFN-γ ELISpot kits to evaluate spike protein-specific T cell responses pre- and post-vaccination.

In the assays, PBMCs were stimulated with spike protein overlapping peptide pools (S1 and S) spanning the entire vaccine inserts. Although the peptide pools used were not ours, we have similar products available.

We look forward to the phase 3 studies emerging from these initial clinical trials.

Explore similar topics

Highlighted research ELISpotHumanIFN-γVaccines for infectionsSARS-CoV-2Publication